A cute cerebral ischemia is a major cause of human suffering, hospitalization, chronic disability, and death. The past few years have shown the crucial role of inflammation in the pathophysiology of atherosclerosis 1 and its clinical manifestations, ie, coronary artery disease, peripheral artery disease, and stroke. Atherosclerosis involves inflammatory cells (ie, T cells, monocytes/macrophages) in the vasculature as well as the systemic elevation of proinflammatory cytokines, chemokines, adhesion molecules, and tissue factor. 2 Another important feature of advanced stages of atherosclerosis is the formation of an intravascular thrombus, which plays a central role, particularly in the setting of acute coronary or cerebral ischemia, as shown by histopathologic and interventional studies. 3 Interestingly, the intricate interface between inflammation and thrombosis is currently becoming apparent. 4 Platelets produce a variety of inflammatory mediators, such as platelet-derived growth factor, platelet factor 4, thrombospondin, transforming growth factor-␤, and nitric oxide, thus contributing to the vascular inflammation during the formation of an intravascular thrombus. 4 Hereby, antithrombotic treatment might suppress inflammation.
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So far, the underlying mechanisms for the proinflammatory and prothrombotic milieu found in acute coronary or cerebral ischemia are only partially understood. Recently, studies have supported the emerging role of the CD40-CD40 ligand (CD40L-CD154) interactions in atherosclerosis, thrombosis, and inflammation. 5 The CD40-CD154 dyad was originally known to be essential in immune reactions and autoimmune diseases. 5 In atherosclerosis, disruption of the CD40-CD154 system in LDL receptor-or apoE-deficient mice prevents initiation of atherosclerosis and progression of established atherosclerotic lesions to more advanced lesions. 6 Structurally, CD154 is a transmembrane protein related to tumor necrosis factor-␣ and was originally identified on stimulated CD4
ϩ T cells and later, on stimulated mast cells, basophils, and platelets, 7 as well as vascular cells like smooth muscle cells. 8 The receptor CD40 is constitutively expressed on B cells, monocytes, macrophages, dendritic cells, and endothelial cells. 8, 9 Engagement of CD40 on endothelial cells or monocytes induces the synthesis of adhesion molecules, proinflammatory cytokines, chemokines, and tissue factor or activates matrix metalloproteinases. 6, 7 In addition, CD154 is strongly upregulated on platelets constituting a fresh thrombus. 7 Thus, the CD40-CD154 system appears to be a critical pathway for local inflammation of the vascular wall and the hemostatic system.
Whereas the role of CD40-CD154 in acute coronary syndromes has been proven recently, 10 no study has addressed the potential relation between acute cerebral ischemia and the CD40 system. Therefore, the present study was designed to investigate whether the CD40-CD154 dyad is modified in patients with transient ischemic stroke (TIA)/stroke with regard to platelets, monocytes, and T cells. In addition, prothrombotic and proinflammatory parameters, such as platelet-monocyte aggregates and monocyte chemoattractant peptide-1 (MCP-1), which have been closely linked to the CD40 system, were studied.
Methods

Patients and Controls
The study contained 60 patients with ischemic stroke and 17 patients with a TIA who were admitted to the stroke unit of the Department of Neurology at the University of Erlangen-Nuremberg within 24 hours after the onset of symptoms. Patients with symptoms lasting for Ͼ24 hours were excluded from the study. Further exclusion criteria were infections, malignancies, autoimmune diseases, acute coronary syndromes, surgery within the previous 12 months, and intracerebral hemorrhage. A detailed history was obtained (see Table  1 ). Blood concentrations of leukocytes, platelets, and C-reactive protein (CRP) were determined.
Standard diagnostic measures included cranial computed tomography to exclude intracerebral hemorrhage, duplex sonography to confirm or exclude significant stenosis of the extracerebral and intracerebral carotid arteries, and electrocardiography for the detection of arrhythmias, as well as echocardiography for the exclusion of intracardiac thrombus. Acute cerebral ischemias were classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 11, 12 Patients admitted within 3 hours after onset of symptoms underwent thrombolysis according to an in-house standard protocol of the stroke unit based on the National Institute of Neurological Disorders and Stroke criteria and AHA guidelines. 13 The control group consisted of 15 sex-and agematched subjects with no clinical signs of acute coronary, peripheral, or cerebral ischemia within the 12 months preceding study entrance and with a comparable atherosclerotic risk profile. The local ethics committee approved the study, and the patients gave their written, informed consent.
Blood Sampling Protocol
Peripheral venous blood was drawn by physicians into bloodcollection tubes containing sodium citrate within 6 hours after admission and before the administration of any medications, including thrombolytic agents. Blinded blood samples were either centrifuged (190g, 10 minutes, room temperature [RT]) by the laboratory assistants to obtain platelet-rich plasma or immediately fixed with 1% formaldehyde (1:1, vol/vol). Noncitrated blood was immersed in melting ice and allowed to clot for 1 hour before centrifugation (1500g, 10 minutes, 4°C). The supernatant was stored at Ϫ80°C until analysis. Samples were thawed only once.
Immunofluorescence
The following antibodies were used: fluorescein isothiocyanate Platelet immunostaining was performed as previously described. 14 Fixed blood was diluted 1:200 with phosphate-buffered saline and incubated with the antibodies for 30 minutes at RT. In some experiments, we used platelet-rich plasma for the stimulation of platelets (20 000/L) with ADP (5 mol/L, for 10 minutes at RT; ADP from Sigma). Thereafter, platelets were diluted to 2500/L and incubated with the antibodies (anti-CD154, anti-CD62P [directed at P-selectin] and anti-CD61 [directed at the membrane glycoproteins ␣IIb␤3 and ␣ v␤ 3 on platelets]) for another 30 minutes at RT. A total number of 10 000 cells was measured by flow cytometry (FACSCalibur, Becton- Platelets were identified by gating on CD61-PE (ie, P-selectin) positivity and their characteristic light scatter. The platelet population evaluated was found to be Ն98% positive for CD61, and the FACS intratest variability was Ͻ10%. Before starting the study, experiments had excluded the possibility that the fixation procedure with 1% formaldehyde significantly altered the expression of any of the epitopes measured.
For the evaluation of CD40 on monocytes, fixed blood was diluted 1:5 and incubated with anti-CD40 and anti-CD14 (for identification of monocytes) for 30 minutes at RT. To determine T-cell activation, fixed blood was incubated with anti-CD4 (for identification of CD4 ϩ T cells) and anti-CD25 (for identification of interleukin-2 receptor as a marker of T-cell activation). Erythrocytes were removed by adding 2 mL FACS lysis solution (PharMingen) for 10 minutes at RT. Leukocytes were washed twice with phosphate-buffered saline and fixed in 1% formaldehyde in phosphate-buffered saline. Monocytes were identified by gating for CD14 ϩ cells and T cells, by gating for CD4 ϩ cells. Adhesion of platelets to monocytes was measured as previously described. 15 In brief, 100 L citrate-anticoagulated blood was diluted with HEPES-Tyrode's buffer (1:2, vol/vol). Samples were incubated with anti-CD61 or isotype-matched control. After 30 minutes of incubation at RT, 1 mL FACS lysis solution was added for 10 minutes to lyse erythrocytes before analysis by flow cytometry. Plateletmonocyte aggregates were identified by gating on the monocyte population.
Measurement of Soluble CD154 and MCP-1
Serum (MCP-1) levels and plasma (sCD154) levels were analyzed in duplicates by using commercially available ELISAs (sCD154 detection limit, 95 pg/mL, Bender MedSystems; MCP-1 detection limit, 5 pg/mL, R&D) according to the manufacturers' instructions.
Statistics
The data were analyzed by nonparametric methods to avoid assumptions about the distribution of the measured variables. Comparisons between groups and within groups were made with the MannWhitney U test and Kruskal-Wallis test, respectively. The differences between baseline and posttreatment values were analyzed with the Wilcoxon signed-rank test. The association of measurements with other biochemical parameters was assessed by the Spearman rank correlation test. All values are reported as meanϮSD. Statistical significance was considered to be indicated by a value of PϽ0.05.
Results
The data in Table 1 show the baseline characteristics of the study groups. Etiology of stroke according to the TOAST criteria was large-artery atherosclerosis in 26.7% (16 of 60 patients) of all patients with stroke, cardioembolism (21.7%, 13/60 patients), small-artery occlusion (30%, 18/60 patients), stroke of other determined cause (5%, 3/60 patients), and stroke of undetermined cause (16.7%, 10/60 patients).
CD154 on platelets was significantly increased in formaldehyde-fixed blood samples from patients with TIA and stroke compared with those obtained from control subjects (CD154: control, 9.5Ϯ5.8; TIA, 32.3Ϯ20.7; and stroke, 25.8Ϯ16.3; all net MFI; TIA vs control, PϽ0.001; stroke vs control, PϽ0.001; and TIA vs stroke, Pϭ0.09; Figure 1A ). The percentage of platelets positive for expression of CD154 in each patient with TIA or stroke was also significantly higher than in the control subjects (control, 4.9Ϯ4.3%; TIA, 17Ϯ5.6%; and stroke, 18.2Ϯ11.8%; TIA vs control, PϽ0.001; stroke vs control, PϽ0.001; and TIA vs stroke; Pϭ0.8, Kruskal-Wallis test).
Next to CD154, P-selectin on platelets was significantly upregulated in patients with stroke but not significantly upregulated in patients with TIA compared with controls (control, 1.2Ϯ0.6; TIA, 2.3Ϯ1.8; and stroke, 3.5Ϯ3.5 MFI; TIA vs control, Pϭ0.9; stroke vs control, PϽ0.01; and TIA vs stroke, Pϭ0.2, KruskalWallis test). Upregulation of both CD154 and P-selectin on platelets did not depend on the etiology of stroke (data not shown). Furthermore, stimulation of unfixed platelets with the agonist ADP increased the expression of CD154 as well as of P-selectin in platelets obtained from patients with TIA and stroke and those from controls (Table 2) .
At 3-month follow-up, expression levels of CD154 in patients with TIA were even more elevated at this time (24.3Ϯ7.3 vs 39.3Ϯ13.7 MFI; Pϭ0.01), whereas patients with stroke showed no significant change in CD154 expression levels at follow-up (20.9Ϯ15.8 vs 29.3Ϯ26.2 MFI; Pϭ0.3). In addition, P-selectin showed an unchanged, elevated expression level in patients with TIA and stroke at the 3-month follow-up (for TIA, initial event, 2.3Ϯ0.9 vs follow-up, 2.9Ϯ3.9 MFI, Pϭ0.8; for stroke, 3.4Ϯ2.5 vs 4.1Ϯ2.9 MFI, Pϭ0.4). Interestingly, throughout the study groups, the expression of CD154 on platelets showed a significant correlation with the expression of P-selectin (rϭ0.29,
PϽ0.05).
The soluble and biologically active form 16 of CD154 (sCD154) showed significantly higher plasma levels in patients with TIA and stroke compared with controls (control, 3.4Ϯ1.6; TIA, 16.9Ϯ7; and stroke, 17.1Ϯ7.5 ng/mL; TIA vs control, PϽ0.001; stroke vs control, PϽ0.001; and TIA vs stroke, Pϭ0.9; Figure 1B ). At the 3-month follow-up, plasma levels of sCD154 did not decline significantly (TIA initial event, Upregulation of CD40-CD154 might enhance the release of MCP-1 from endothelial cells or monocytes in vitro. 16 Accordingly, patients with TIA (278.7Ϯ184.1 pg/mL) and stroke (267.2Ϯ117.6) showed significantly higher serum levels of MCP-1 than did controls (158.7Ϯ100.6; TIA or stroke vs control, PϽ0.05; and TIA vs stroke, Pϭ0.5; Figure 4 ). At the 3-month follow-up, serum concentrations of MCP-1 were almost unchanged in the patient groups (acute ischemic event, 267.2Ϯ117.6 vs 3-month follow-up, 246.7Ϯ102.2 pg/mL, Pϭ0.6). Correlation analysis, however, revealed no significant correlation among platelet CD154, number of CD154 ϩ platelets, or sCD154 and serum concentrations of MCP-1 (CD154: rϭ0.05, Pϭ0.7; and sCD154: rϭ0. 16, Pϭ0.3) .
17.5Ϯ7.4 vs follow
Next to platelets and monocytes, patients with acute cerebral ischemia showed a significant higher activation of CD4 
Discussion
The present study shows CD40-CD154 upregulation in patients with acute cerebral ischemia: patients showed a significant increase of CD154 expression on platelets and T cells and of CD40 on monocytes when compared with sex-and age-matched controls. Activation of platelets and monocytes led to significantly higher numbers of platelet-monocyte aggregates. The role of the CD40 system in acute cerebral ischemia was further supported by the finding of significantly elevated plasma levels of the soluble form of CD154 in patients with TIA and with stroke. Both forms of CD154 might be responsible for the elevation of MCP-1, which we found to be significantly elevated in acute cerebral ischemia. Although activation of the CD40 system has been observed in atherosclerosis-related diseases, 16, 6 our findings represent the first in vivo evidence of CD40-CD154 upregulation in patients with acute cerebral ischemia. These data represent an additional pathophysiological pathway for the prothrombotic and proatherogenic state found in patients with TIA and stroke.
Our results confirm several studies that have shown that acute cerebral ischemia is associated with persistent platelet activation in vivo. 17, 18 The upregulation of CD154 on platelets, however, represents a new pathophysiological aspect in acute cerebral ischemia. 7 P-selectin and CD154 derived from platelets share common features but show biologic differences: both can be immediately expressed on platelets on stimulation with platelet activators. In contrast to previous reports, 7 CD154 in platelets is not stored in the ␣-granule, as is the case for P-selectin, but in the cytosol of platelets and follows a different expression pattern on platelet activation compared with P-selectin. 19 Moreover, enzymatic cleavage of membrane-bound CD154 on platelets leads to a rise in soluble CD154, because it was detected in the plasma of our patients with TIA and with stroke. 20 Given its strong capability of inducing proinflammatory, prothrombotic, and proatherosclerotic effects in the vasculature, a prominent role for CD154 as a major pathophysiological contributor has to be assumed in the setting of acute cerebral ischemia.
The activation of monocytes in acute cerebral ischemia with consecutive release of proinflammatory mediators has been reported previously. 21 Particularly CD40 engagement on monocytes induces many procoagulant and proatherosclerotic effects. 22 CD40 on monocytes might be upregulated by proinflammatory mediators, such as CRP. 16 The latter was found to be elevated in acute cerebral ischemia. 23 CD40 engagement on monocytes might also occur through enhanced platelet-monocyte interaction, because monocytes rapidly adhere for prolonged periods of time to activated platelets that display P-selectin. 25 This enhanced interaction between platelets and monocytes increases, through the engagement of CD40, the release of proinflammatory and prothrombotic factors. Moreover, elevated numbers of platelet-monocyte aggregates have been shown to be a stronger predictor of thrombosis compared with P-selectin. 25 Our finding of an activation of T cells in acute cerebral ischemia indicates that T cell-derived CD154 might contribute to inflammation in this setting. The observed significant elevation of serum levels of sCD154 in patients with acute cerebral ischemia might therefore not only derive from activated platelets but also from activated T cells.
In addition, we found significantly elevated serum levels of MCP-1, an important chemokine that specifically attracts leukocytes to sites of inflammation. This result stands in contradiction to the study of Losy and Zaremba, 26 in which patients with ischemic stroke showed significantly elevated MCP-1 levels in their cerebrospinal fluid but not in their sera. In our larger study, the finding of elevated serum levels of MCP-1 fits into the pathophysiological concept of an ongoing inflammatory process in the setting of acute ischemic syndromes. 23 For example, CRP as an established marker of inflammation in these states induces MCP-1 from endothelial cells. 24 The MCP-1 release might also be the result of CD40 engagement on endothelial cells 27 or on monocytes. 28 In an in vitro platelet-endothelial cell coculture model, CD154 on platelets proved its biologic potency by significantly enhancing the release of MCP-1 from human endothelial cells. 16, 17 An important finding of our study is the persistence of upregulation of CD154 and MCP-1 even 3 months after the initial event. Van Kooten et al 29 have reported persistent platelet activation in the chronic phase after stroke as a parameter of poor clinical outcome. Persistent upregulation of CD154 with its known prothrombotic and proinflammatory effects might possibly be another determinant for poor clinical outcome, as has been shown for patients with acute coronary syndromes. 10 Specific therapeutic interventions can suppress CD40-mediated proatherogenic effects, because it has been already shown in animal models. 6 With regard to platelets, ADPreceptor agonists such as clopidogrel completely abolish CD154 upregulation, whereas aspirin, the most widely used "antiplatelet" agent in acute cerebral ischemia, does not inhibit CD154 expression. 19 This observation further supports the potential benefit of new developed antithrombotic substances in the setting of acute cerebral ischemia. 30 With regard to monocytes and the endothelium, CD40 upregulation can be effectively suppressed by statins. 16 Our present data provide another rationale for the potential benefit of statins in the acute phase of cerebral ischemic disease, as has been recently proven in the setting of acute coronary syndromes. 31 Current studies in patients with acute cerebral ischemia treated with statins will prove this. 32 A possible limitation of our present study consists of the rather small control group. Hypertensive subjects were particularly underrepresented compared with the study groups.
In conclusion, we have shown that acute cerebral ischemia is associated with activation of the CD40-CD154 system. Because upregulation of this system is particularly involved in the advanced stage of atherosclerosis, including plaque rupture, we propose that activation of the CD40-CD154 system might create and/or maintain the proinflammatory and prothrombotic milieu found in patients with TIA or stroke. Targeting the CD40-CD154 system in acute cerebral ischemia through specific pharmacologic interventions might result in a clinical benefit for these patients.
Editorial Comment
Stroke and the CD40-CD40 Ligand System: At the Hinge Between Inflammation and Thrombosis
Mounting evidence indicates that procoagulant and inflammatory pathways intertwine in complex networks and that inflammation contributes in an important way to atherogenesis and arterial thrombosis, ultimately leading to diseases such as ischemic stroke. Among the most intriguing recent findings was the detection of an important role of the potent immune mediator CD40 and its counterpart CD40 ligand (CD 154) in thrombosis and atherosclerosis. Initially thought of as solely mediating T lymphocyte-B lymphocyte interactions, CD40 was later also detected on monocytes/macrophages, smooth muscle cells, and endothelial cells. CD40 is an important activation receptor, whose engagement via CD40L endows these cells with powerful functions including the release of proinflammatory cytokines, adhesion receptors, tissue factor, metalloproteinases, and prostaglandins. CD40L, a transmembrane protein structurally related to tumor necro-
